OPNT - OPNT STOCK NEWS

Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q4 2020 revenues of $10 million, a rise from $7.7 million in Q4 2019, contributing to a full-year revenue of $29.6 million, down from $40.5 million in 2019. The company focuses on treatments for addictions and overdoses, advancing OPNT003 for opioid overdose with significant milestones expected in 2021. Despite a $1.9 million net loss in 2020, Opiant secured $50 million in convertible debt financing to enhance financial flexibility. Ending 2021 is projected with $40 million in cash despite lower 2021 royalty expectations from NARCAN®.

Opiant Pharmaceuticals (NASDAQ: OPNT) will report its financial results for Q4 and the full year ended December 31, 2020, on March 4, 2021, post-market. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will discuss these results. Investors can access the call via phone or webcast on the company’s website. Opiant is known for its development of medications addressing addictions and drug overdose, including the NARCAN® Nasal Spray.

Opiant Pharmaceuticals has initiated a confirmatory pharmacokinetic study for OPNT003, a nasal nalmefene formulation aimed at treating opioid overdoses. The first patient was dosed in February 2021, with results expected by June 2021. The study focuses on comparing the pharmacokinetic profiles of intranasal and intramuscular nalmefene. This new treatment method is crucial as overdose deaths from synthetic opioids like fentanyl are rising. Opiant plans to file a New Drug Application with the FDA for OPNT003 by late 2021, supported by grants from NIH and BARDA.

Opiant Pharmaceuticals (NASDAQ: OPNT) announced a $3.5 million commitment from BARDA, increasing the total funding for OPNT003 to $8.1 million, aimed at enhancing clinical development for opioid overdose treatment. OPNT003, nasal nalmefene, is anticipated to be a key rescue agent against synthetic opioids like fentanyl. The full regulatory submission to the FDA is expected by late 2021. Previous grants from the National Institute on Drug Abuse further support this initiative, which also addresses potential use in mass casualty scenarios.

Opiant Pharmaceuticals (NASDAQ: OPNT) has secured a $50 million financing through a convertible Note Purchase Agreement with Pontifax Medison Finance and Kreos Capital. The funds will support the commercialization of OPNT003, a nasal nalmefene for opioid overdose, with an FDA submission planned for late 2021. The financing is structured in three tranches, with the first tranche of $20 million already funded. Opiant aims for sufficient financial flexibility to launch OPNT003 without additional financing, bolstered by $31.1 million in existing cash.

Opiant Pharmaceuticals (NASDAQ: OPNT) announced the appointment of Craig A. Collard as Chairman of its Board of Directors, effective January 1, 2021. With over 20 years in the biopharmaceutical sector, Collard brings significant experience, having previously served as CEO of multiple pharmaceutical companies. His leadership is expected to bolster Opiant's mission to deliver new medicines for addiction and drug overdose, especially with its lead candidate, OPNT003, aimed at treating opioid overdose. Gabrielle Silver, the current Lead Independent Director, will continue her role as an independent board member.

Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q3 2020 revenues of $9.1 million, down from $20.6 million in Q3 2019, primarily due to a significant milestone payment received in the prior year. The company recognized approximately $8.6 million in royalties from NARCAN® Nasal Spray, which saw sales of $88.8 million. Projected full-year royalties have been raised to $28 million. The company plans to file a New Drug Application for OPNT003 by the end of 2021. As of September 30, 2020, cash and cash equivalents totaled $31.1 million, stable compared to last year.

Opiant Pharmaceuticals, a specialty pharmaceutical firm focused on addiction and drug overdose treatments, announced that CEO Dr. Roger Crystal will present at the Jefferies 2020 Virtual London Healthcare Conference on November 19, 2020, at 6:45 pm GMT. Management will also hold virtual one-on-one meetings throughout the conference, occurring from November 17-19, 2020. Investors and the public can access a live audio webcast of the presentation on the Opiant website, with a replay available for 90 days post-event.

Opiant Pharmaceuticals (NASDAQ: OPNT) has partnered with Aptar Pharma to develop OPNT003, a nasal nalmefene intended for the treatment of opioid overdose, utilizing Aptar's FDA-approved Unit Dose System. This collaboration underscores Opiant’s commitment to addressing the escalating opioid crisis in the U.S. The company plans to submit a New Drug Application (NDA) for OPNT003 by the end of 2021. The development is supported by grants from the NIH and BARDA, focusing on nalmefene as a potential antidote for mass casualty events.